Comparative Analysis Of Newer Oral Anticoagulants In The Management Of Coronary Artery Disease: Safety And Efficacy In An Intensive Care Setting

Abstract

This study evaluated the clinical efficacy, safety, and patient satisfaction associated with Warfarin, Apixaban, and Dabigatran in patients requiring long-term anticoagulation therapy. A comparative analysis was conducted using a randomized study design involving three patient groups. Key clinical parameters, including thrombotic events, bleeding complications, hypersensitivity reactions, and treatment compliance, were analyzed. Descriptive statistics were used to report mean values and frequencies, while inferential statistics, including ANOVA and chi-square tests, were employed to determine significant differences between the groups. Apixaban and Dabigatran demonstrated superior safety profiles, with lower Incidences of major bleeding events and higher patient compliance compared to Warfarin. Laboratory findings revealed significant improvements in coagulation markers among patients treated with Apixaban and Dabigatran. Hypersensitivity reactions and dropout rates were lowest in the Apixaban group, reinforcing its favorable safety profile. The study confirmed the hypothesis that direct oral anticoagulants (DOACs) offer enhanced safety and patient satisfaction over Warfarin, supporting the growing clinical preference for these newer agents. The results underscored the importance of individualized treatment strategies to optimize anticoagulation outcomes. The study's findings have broad clinical implications, suggesting that Apixaban and Dabigatran may serve as preferred options in long-term anticoagulation therapy due to their enhanced safety, improved patient adherence, and favorable clinical outcomes. These insights provide a foundation for refining anticoagulation guidelines and advancing patient-centered care strategies in managing thrombotic disorders.